| |
Wednesday, February 26, 2025 | 12pm ET / 9am PT In today’s world, life sciences and healthcare companies face major challenges — managing complex datasets, accelerating drug discovery, and advancing precision research. Register for our webinar to learn how to overcome overcome these challenges using AI cloud infrastructure and advanced machine learning tools.
|
|
Today’s Big NewsFeb 5, 2025 |
|
Wednesday, February 26, 2025 | 11am ET / 8am PT Discover how the convergence of spatial biology, AI, and computational tools is transforming cancer research. This webinar explores high-multiplex spatial analysis, tumor heterogeneity, and advances in precision medicine, reshaping drug development. Register now to learn how these innovations are driving breakthroughs in oncology.
|
|
| By Nick Paul Taylor Novo Nordisk’s cannabinoid CB1 receptor blocker has run into another problem. Months after sharing obesity data that left investors underwhelmed, the Danish drugmaker has reported the failure of a midphase diabetic kidney disease trial of the molecule. |
|
|
|
By Fraiser Kansteiner With sales of Novo Nordisk’s obesity blockbuster Wegovy more than doubling in 2024’s fourth quarter, the Danish drugmaker feels confident that it can maintain its edge over chief rival Eli Lilly in the year to come. Still, the company caveated that it expects sales growth in 2025 to be a bit milder than last year. |
By Angus Liu After re-adding Blenrep to its portfolio, GSK now expects sales to reach more than £40 billion in 2031. The company's previous target was £38 billion. |
By Darren Incorvaia Amgen’s mysterious obesity asset will remain a mystery for a bit longer—the FDA has put the candidate’s phase 1 trial on a clinical hold, the biotech announced Feb. 4. Amgen didn’t disclose the reason for the hold. |
|
Thursday, February 27, 2025 | 2pm ET / 11am PT The quest to discover biomarkers for therapeutic response through traditional genomic sequencing and other omic approaches has yet to deliver clinically actionable tools for most patients. Don’t miss this compelling discussion on how cutting-edge glycoproteomic technologies are unlocking new clinical insights.
|
|
By Conor Hale That includes treating more than 200,000 patients with the irregular heartbeat known as atrial fibrillation—and the sum more than makes up for the $295 million that Boston Scientific put down to acquire the technology in mid-2021. |
By Zoey Becker The company is in talks with individual regulatory authorities after its decision to withdraw a European approval application for Izervay prompted a $760 million impairment charge. |
By Andrea Park AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting off on a very different note. |
By Gabrielle Masson Precision medicines biotech Frontier Medicines is leaving behind an unknown number of staffers as it refocuses resources to optimize operations. |
By Zoey Becker The device is meant to allow patients more control over their "off" time, or the instances when medicine wears off and symptoms return or worsen. |
By James Waldron GSK is prioritizing development of its hepatitis B treatment bepirovirsen, even as the pharma ends work on another potential functional cure for the infectious disease. |
By Nick Paul Taylor The CDC Foundation has added muscle to its “Live to the Beat” campaign, enlisting former NFL star Jerome “The Bus” Bettis to drive home its message about heart disease in the Black community. |
By Conor Hale Glucotrack has cleared the first human clinical study of its long-term continuous glucose monitoring implant, designed to live under the skin for as long as three years. |
By Nick Paul Taylor Amar Urhekar has reset Avalere Health’s mission. Weeks after naming Urhekar as CEO, the biopharma commercialization partner has aligned its teams behind the goal of ensuring “every patient is identified, supported, treated and cared for.” |
By Kevin Dunleavy After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion by the end of the decade. |
By Andrea Park As Moderna maps out a more cautious future amid lower-than-expected sales of its current products, the company is bolstering its marketing team. |
Fierce podcastsDon’t miss an episode |
| | As the first two weeks of his second term showed, keeping up with Trump’s actions—and their ramifications—requires full-time focus. A policy expert breaks down how Congress might approach reform in 2025. |
|
|---|
|
|
| WhitepaperThis paper reviews key developments in the oncology market during 2024 and outlines what they mean for the future. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
